AstraZeneca Annual Report and Operational Review 24 Form 20-F Information 2003 Development Pipeline Phase Estimated filing date Compound Mechanism Areas under investigation PC 1 2 3 MAA NDA Cardiovascular NCEs Exanta thrombin inhibitor prevention of VTE Approved Filed Exanta SC formulation thrombin inhibitor sc prevention of VTE Approved 2006 Galida PPAR agonist diabetes metabolic syndrome 2006 2006 AZD6140 ADP receptor antagonist arterial thrombosis 2006 2006 AZD7009 ARDA atrial fibrillation 2006 2006 AZD9684 CPU inhibitor thrombosis 2006 2006 AZD0837 thrombin inhibitor thrombosis 2006 2006 AZD7806 IBAT inhibitor dyslipidaemia 2006 2006 AZD6610 dyslipidaemia 2006 2006 AZD4619 dyslipidaemia 2006 2006 AZD0303 thrombosis 2006 2006 AZD8294 dyslipidaemia 2006 2006 Line Extensions Atacand angiotensin II antagonist CHF outcomes CHARM study 2Q 2004 2Q 2004 diabetic retinopathy 2006 2006 Crestor statin atheroma 2006 2006 outcomes CHF 2006 2006 outcomes renal 2006 2006 Seloken Toprol-XL beta blocker HCTZ combination 1H 2005 Exanta thrombin inhibitor prevention of stroke in AF Filed Filed treatment of VTE Filed 2006 arterial post MI 2006 2006 France, Reference Member State for the EU Mutual Recognition Procedure.
Gastrointestinal NCEs AZD0865  acid blocker acid related GI disease 2006 2006 AZD3355 inhibitor of TLESR GERD 2006 2006 AZD7371 functional GI disorders 2006 2006 AZD9343 inhibitor of TLESR GERD 2006 2006 Line Extensions Nexium proton pump inhibitor NSAID GI side effects symptom resolution Promotable Filed parenteral formulation Approved Filed NSAID GI side effects healing and prevention Filed Filed extra-oesophageal reflux disease 2006 2006 Authorities stated these symptoms were already captured within the GERD label.
Text stating No clinical interaction with naproxen or rofecoxib was approved.
Infection Line Extensions Merrem carbapenem antibiotic skin and soft tissue infections 2Q 2004 Neuroscience NCEs Cerovive free radical trapping agent stroke 2006 2006 previously NXY059 ZD0947 K channel opener overactive bladder 2006 2006 AR-A2 5HT antagonist anxiety depression 2006 2006 1B AZD4282 NMDA antagonist neuropathic pain 2006 2006 AZD4750 chemokine receptor inhibitor multiple sclerosis 2006 2006 AZD5455 anxiety disorders 2006 2006 AZD0328 alpha-7 nicotinic receptor agonist Alzheimers disease 2006 2006 AZD2858 Alzheimers disease 2006 2006 AZD3102 Alzheimers disease 2006 2006 Line Extensions Zomig 5-HT receptor agonist nasal spray Launched Launched 1B 1D Seroquel D 5HT antagonist bipolar mania Approved Approved 2 2 sustained release 2H 2005 2H 2005 bipolar maintenance 2006 2006 bipolar depression 2006 2006 granules 2006 2006 AstraZeneca Annual Report and Operational Review Form 20-F Information 2003 25 Phase Estimated filing date Compound Mechanism Areas under investigation PC 1 2 3 MAA NDA Oncology NCEs Faslodex oestrogen receptor antagonist 2nd line advanced breast cancer Filed Launched Iressa EGFR-TK inhibitor NSCLC Filed Launched ZD6474 angiogenesis inhibitor VEGFR-TKI solid tumours 2006 2006 ZD4054 endothelin A receptor antagonist solid tumours 2006 2006 ZD6126 vascular targeting agent solid tumours 2006 2006 AZD2171 angiogenesis inhibitor VEGFR-TKI solid tumours and haematological malignancies 2006 2006 AZD3409 farnesyl-transferase inhibitor solid tumours 2006 2006 AZD0530 SRC kinase inhibitor solid tumours 2006 2006 AZD5438 selective cyclin dependent kinase inhibitor solid tumours 2006 2006 AZD4440 vascular targeting agent solid tumours 2006 2006 AZD9935 angiogenesis inhibitor VEGFR-TKI solid tumours 2006 2006 AZD0424 SRC kinase inhibitor solid tumours 2006 2006 AZD1152 aurora kinase inhibitor solid tumours 2006 2006 AZD6244 MEK inhibitor solid tumours 2006 2006 Line Extensions Faslodex oestrogen receptor antagonist 1st line advanced breast cancer 2006 2006 Iressa EGFR-TK inhibitor head and neck cancer 2006 2006 breast cancer 2006 2006 colorectal cancer 2006 2006 Respiratory and Inflammation NCEs AZD9056 ion channel blocker rheumatoid arthritis 2006 2006 AZD8309 chemokine receptor antagonist rheumatoid arthritis 2006 2006 AZD8309 chemokine receptor antagonist COPD 2006 2006 AZD9056 ion channel blocker COPD 2006 2006 AZD3342 protease inhibitor COPD 2006 2006 AZD0902 ion channel blocker COPD 2006 2006 AZD0902 ion channel blocker rheumatoid arthritis 2006 2006 AZD9056 ion channel blocker osteoarthritis 2006 2006 AZD8955 collagenase inhibitor osteoarthritis 2006 2006 AZD3778 asthma rhinitis 2006 2006 AZD6067 COPD 2006 2006 AZD2098 asthma 2006 2006 AZD1981 asthma 2006 2006 Line Extensions Symbicort Turbuhaler inhaled steroid fast onset, single therapy for asthma Filed long-acting beta agonist 2 Symbicort pMDI inhaled steroid fast onset, asthma 2Q 2004 2005 long-acting beta agonist 2 COPD 2Q 2004 2006 Comments As disclosure of compound information is balanced by the business need to maintain confidentiality, some compound information has not been disclosed at this time.
Compounds in development are displayed by phase.
Abbreviations: Discontinued projects: MEK mitogen activated extra-cellular signal-regulated 5HT 5-hydroxytryptamine serotonin kinase kinase AZD1134 anxiety depression 5HT 1B subtype of 5HT receptor MI myocardial infarction AZD3582 acute chronic nociceptive pain 1B 5HT 1D subtype of 5HT receptor NCE new chemical entity AZD4717 acute chronic nociceptive pain 1D 5HT 2 subtype of 5HT receptor NDA new drug application US AZD5106 overactive bladder 2 ADP adenoside diphosphate NMDA N-methyl-D-aspartate AZD0275 rheumatoid arthritis COPD AF atrial fibrillation NSAID non-steroidal anti-inflammatory drug AZD7140 rheumatoid arthritis COPD ARDA atrial repolarisation delaying agent NSCLC non-small cell lung cancer Oxis pMDI asthma CHF congestive heart failure PC pre-clinical: candidate drug accepted for COPD chronic obstructive pulmonary disease development but not yet administered to man CPU carboxy peptidase-U pMDI pressurised metered dose inhaler D 2 subtype of dopamine receptor PPAR peroxisome  receptor 2 EGFR-TKI epidermal growth factor receptor-tyrosine sc subcutaneous kinase inhibitor TLESR transient lower oesophageal sphincter GERD gastro-oesophageal reflux disease relaxations GI gastrointestinal VEGFR-TKI vascular endothelial cell growth factor HCTZ hydrochlorothiazide receptor-tyrosine kinase inhibitor IBAT ilial bile acid transport VTE venous thromboembolism K potassium 2006 not earlier than 2007 MAA marketing authorisation application Europe
